论文部分内容阅读
目的分析在早期糖尿病足患者治疗中联合应用前列地尔与胰激肽原酶治疗的效果。方法收集2014年1月—2015年12月在该院治疗的早期糖尿病足患者74例,依据治疗方式的差别分成单治组与联合组,各组37例,单治组患者单纯使用前列地尔治疗,联合组患者则在单治组患者治疗的基础上采用胰激肽原酶进行治疗,对比两组治疗的效果。结果联合组患者治疗的总有效率和单治组患者相比,数值明显比联合组大,组间对比差异有统计学意义(P<0.05)。结论在早期糖尿病足患者治疗中联合应用前列地尔与胰激肽原酶治疗,能够提高临床治疗的效果。
Objective To analyze the effect of combined application of prostaglandin and pancreatic kininogenase in the treatment of patients with early diabetic foot. Methods 74 patients with early diabetic foot treated in our hospital from January 2014 to December 2015 were divided into single treatment group and combined treatment group according to the difference of treatment methods. There were 37 patients in each group. The patients in single treatment group were treated with alprostadil Treatment, the combined group of patients in the treatment group based on the treatment of pancreatic kallikrein, comparing the effect of the two groups of treatment. Results The total effective rate of treatment in combination group was significantly higher than that in combined treatment group (P <0.05). Conclusions The combination of prililipid and kallidinogenase in the treatment of patients with early diabetic foot can improve the effect of clinical treatment.